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Abstract: As a complex disease, Multiple Sclerosis (MS)’s etiology is determined by both genetic
and environmental factors. In the last decade, the gut microbiome has emerged as an important
environmental factor, but its interaction with host genetics is still unknown. In this review, we focus
on these dual aspects of MS pathogenesis: we describe the current knowledge on genetic factors
related to MS, based on genome-wide association studies, and then illustrate the interactions between
the immune system, gut microbiome and central nervous system in MS, summarizing the evidence
available from Experimental Autoimmune Encephalomyelitis mouse models and studies in patients.
Finally, as the understanding of influence of host genetics on the gut microbiome composition in MS is
in its infancy, we explore this issue based on the evidence currently available from other autoimmune
diseases that share with MS the interplay of genetic with environmental factors (Inflammatory
Bowel Disease, Rheumatoid Arthritis and Systemic Lupus Erythematosus), and discuss avenues for
future research.
Keywords: Multiple Sclerosis; gut microbiome; host genetics; dysbiosis
1. Introduction
Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease that causes
demyelination of oligodendrocytes in the Central Nervous System (CNS) [1]. MS is to-
day the leading cause of non-traumatic disabilities in young adults in Europe [2] with a
prevalence of over 2 million cases worldwide [3]. Epidemiology studies have shown a sex
difference in the prevalence and progression of the disease: MS has a 2:1~3:1 female to
male ratio [4]. The relapsing form of MS is more frequent in young women [5] while in
men MS shows higher incidence at older ages and a more severe progressive course [6].
The current definition of the immunopathogenesis of MS describes the initial activation
of self-reactive T and B lymphocytes in the peripheral lymph nodes and their differentiation
into effector cells. T lymphocytes, in particular CD4 + T cells, are the most involved in MS
pathogenesis [7,8]. Pro-inflammatory T helper cells (Th) 1, Th 17 and Th 22 are activated in
the periphery following a deficit of regulatory T lymphocytes (T reg), which lose the ability
to suppress the autoreactive response [9]. Remarkably, MS patients show an increased
count of Th17 cells in the peripheral blood [7], cerebrospinal fluid and perivascular space in
the CNS [8,10–12], following an invasion of the CNS through the blood-brain barrier (BBB).
The disruption of the BBB is recognized as an important early feature of MS pathogenesis.
T and B cells cross the BBB, which is discontinuous, and access the CNS where antigen
presenting cells (APC) reactivate them. In the CNS, the activated immune system reacts
against myelin components. Inflammation is supported by the production of cytokines and
chemokines and by the recruitment of other self-reactive cells from the peripheral blood. In
Genes 2021, 12, 1181. https://doi.org/10.3390/genes12081181 https://www.mdpi.com/journal/genes
Genes 2021, 12, 1181 2 of 18
particular, activated B cells mature into plasma cells and produce antibodies, maintaining
and reactivating CD4 + T cells that produce proinflammatory cytokines. In the later stages
of the disease, the inflammatory response is supported by the activation and polarization
of microglia, leading to chronic neurodegeneration [1,13,14].
To date, the etiology of MS remains largely unknown, but it is considered a multifac-
torial disease in which both genetic and environmental factors could influence the immune
system development and response in individuals, predisposing them to MS onset [3,4].
Although genetics account for ∼30% of disease susceptibility and first-degree relatives
of patients show susceptibility for MS [15,16], MS is not an inheritable disease. Susceptibil-
ity and protective alleles have been identified in the Region of the Major Histocompatibility
Complex (HLA, Human Leukocyte Antigens) and in several genes related to the immune
response [17,18]. Among environmental factors, the most recognized as linked to the
risk of developing MS disease are Epstein–Barr virus (EBV) infection [19,20], smoking
habitude [21] and vitamin D deficiency [22]. Recently, great attention has been paid to gut
microbiome composition [23] and several studies have tried to identify which microor-
ganisms may promote or counter its pathogenesis and progression [24,25]. Interactions
between environmental factors and genes are considered to determine the remaining 70%
of disease risk. How these complex networks of interactions ultimately drive disease
susceptibility remains to be elucidated.
2. Genetic Factors in MS Patients
It is known that the rate of MS recurrence in families is 20%, and concordance between
monozygotic twins is 24–30% while between dizygotic twins is only 3–5%, which is compa-
rable to that of normal brothers [26,27]. Before the era of genome-wide association studies
(GWAS) the only genetic factor implicated in MS susceptibility was on the HLA region
on the short arm of chromosome 6 that extends for about 4 Mb. In particular, a strong
association was observed with the DRB1*15.01 allele, which confers a threefold increase
in risk [28]. Further studies identified other associations with different HLA loci inde-
pendently of the DRB1*1501: the allele HLA-DRB1*0301 and the allele HLA-DRB1*1303,
which confer an MS risk, and the protective allele HLA-A*0201 and a variant that tags
HLA-DPB1*0301 [29]. In the last ten years, international GWAS studies analyzing large
datasets have identified 200 loci involved in susceptibility to the disease separate from
the HLA region. This discovery was mainly due to the contribution of three international
studies in 2011 [18], 2013 [30], and 2019 [31]. In particular, with the latest GWAS study
published in 2019 [31], in which 39,000 individuals from nine different populations were
tested and 331,536 Single Nucleotide Polymorphisms (SNPs) analyzed, the number of
statistically independent associations with MS susceptibility have been increased to 233.
Of these, 32 were within the HLA region, one in chromosome X, and 200 in the autosomal
non-HLA region. The genome-wide and suggestive effects jointly could explain about 48%
of the estimated heritability. This study confirmed the enrichment for MS susceptibility
loci in many different immune cell types and tissues, but on the other hand, it did not find
enrichment in tissue-level CNS profiles. Analyzing data generated from human induced
Pluripotent Stem Cells (iPSC)-derived neurons as well as from purified primary human
astrocytes and microglia, the authors observed that enrichment for MS genes is seen in
human microglia but not in astrocytes or neurons. Despite these efforts in identifying
these associated variants and loci, and although several signals are near genes involved in
immunologic processes, the effector mechanisms for most associations remain unknown.
Until now, very few fine mapping analyses have been conducted to identify a primary
causal variant or gene. Among these, we reported the case of the Interleukin-7 Receptor
(IL7R) gene (rs6897932) [32,33], the case of the Tumor Necrosis Factor (TNF) receptor
superfamily member 1A (TNFRSF1A) gene (rs1800693) [34] and the case of the TNF
Superfamily Member 13B (TNFSF13B) locus (BAFF-var, insertion-deletion) [35]. More
recently, a study published by the International Multiple Sclerosis Genetics Consortium
attempted to examine in depth the role of low-frequency and rare variants in susceptibility
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to MS. This study analyzed 32,367 MS cases and 36,012 controls in detail though an array
platform called Exome chip (Illumina technology), which contains almost 200,000 SNPs
(rare synonymous and non-synonymous SNPs and common synonymous SNPs) mapping
in coding regions enriched in rare variants (MAF < 0.01) [36]. They found a significant
association for seven low-frequency variants in six genes outside the HLA region. Two
of these variants were present in genes identified by MS GWAS and showed linkage
disequilibrium with the common variant previously reported in GWAS [18], while the
remaining signals were novel and did not show linkage disequilibrium with common
variant association signals found through GWAS. The identified genes showed a clear
immunological function, particularly in T cell development. This work demonstrated
that nearly 5% of the heritability of MS can be explained by the already identified coding
low-frequency variants and that more low and rare frequency variant associations remain
to be discovered using larger sample sizes to increase statistical power.
The remaining fraction of the risk commonly known as “missing heritability” is likely
due to still unknown common variants characterized by much smaller effects, below the
detection limits of the GWAS studies conducted so far. Some authors have proposed
that a substantial portion of the missing heritability lies in genetic interactions between
known variants, the so-called phantom heritability [37]. Similarly, gene–environment
interactions, cis/trans-regulators of allelic expression, unidentified rare and penetrant semi-
private variants, population and/or disease heterogeneity, the neglect of the analysis of sex
chromosomes, and hidden epigenetic effects may all contribute to the missing heritability.
3. The Gut Microbiome and MS
3.1. The Human Gut Microbiota
All microorganisms, including bacteria, archaea, fungi, and viruses, exist in an ecosys-
tem called a microbiota, and the collective genomic, protein, and metabolite content of all
the microbes in this given ecosystem is called a microbiome [38]. The human microbiota
colonizes virtually every surface of the human body exposed to the external environ-
ment: skin, urogenital tract, respiratory tract, and digestive tract, but more than 95% of
the microbiota is located in the large intestine. Here, about 1014 different populations of
microorganisms live, with a number of genes at least 100 times larger than the number of
human genes in the body [39]. This large number of intestinal microbes has evolved over a
long period of time, becoming an inseparable part of the host and playing an important
role in maintaining the health of the body.
The relative composition of the gut microbiota can be studied by collecting a stool
sample. After DNA extraction, a following metagenomic analysis is conducted through
two main techniques: analysis of the 16S subunit ribosomal RNA (only for bacteria), or
whole genome sequencing [40,41]. The sequences obtained are not directly identified by
species or phyla, but are classified into Operational Taxonomic Units (OTUs), defined as
groups of microorganisms united by a DNA similarity of at least 97% [41]. The sequences
obtained are mapped onto reference genomes to obtain the relative quantification of
taxa, from which the microbial diversity is derived, or subjected to de novo assembly for
the identification of new phyla [41]. The Metagenomics of the Human Intestinal Tract
and the Human Microbiome Project have provided the most integrated view of human-
associated microbes: 2172 species have been isolated in human gut microbiota [42], and
a healthy gut microbiota is mainly dominated by Bacteroidetes and Firmicutes, while
Proteobacteria, Verrucomicrobia, Actinobacteria and several other phyla are present in
smaller proportions [43].
Gut microbiota and host develop an intimate mutualistic relationship. Normal gut
microbiota is involved in specific functions in host nutrient metabolism: it derives its nutri-
ents from host dietary components and produces source of energy for the host; many taxa
are able to synthetize short chain fatty acids (SCFA) such as butyrate, propionate and ac-
etate from fermentation of carbohydrates that escaped proximal digestion and indigestible
oligosaccharides [44]; it contributes to lipid and protein metabolism, by suppressing the in-
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hibition of lipoprotein lipase activity in adipocytes, and through microbial proteinases and
peptidases acting in tandem with human proteinases [45]; it is also involved in synthesis
of vitamin K and several components of vitamin B. Gut microbiota functions also include
xenobiotic and drug metabolism, maintenance of structural integrity of the gut mucosal
barrier, immunomodulation, and protection against pathogens.
3.2. Factors Influencing the Composition of Gut Microbiota
Changes in the composition of the gut microbiota accompany the individual from
infancy, through adolescence and adulthood, to old age [46]. The first traces of microbial
colonization have been identified in utero, amniotic fluid and placenta although this
remains controversial [47–49]. However, the large-scale colonization of the human intestine
by microbes begins at birth [48,50]. The first differences in microbial composition are
observed between caesarean and natural delivery. Natural childbirth exposes the newborn
to vaginal bacteria, mainly Lactobacillus, while Caesarean section favors contact with the
skin, where Actinobacteria mainly reside [40,48,50]. Further changes are introduced by the
type of feeding (for example breastfeeding or formula feeding and then weaning) [40]. After
the first year of age, an infant microbiota resembles that of a young adult and stabilizes,
but its composition is continuously influenced by endogenous and exogenous factors such
as genetics, sex, diet and drugs. [40,51]. Finally, aging directly acts on the composition of
the microbiota with a decrease in microbial diversity and a decrease in Bifidobacteria and
Firmicutes of the genus Clostridium [50].
Microbial turnover in the adult gut is subject to natural pressures by the host. The
epithelium acts as a physical barrier between microbes and the host’s body by sensing
microbes and mediating the activation of a proper mucosal immune response (innate and
adaptive). It can suppress pathogens using a so-called “punitive mechanism”. Alternatively,
the host can promote proliferation of beneficial microbes through a “positive control”: by
feeding the preferred species via epithelial-derived nutrients or by using secretion factors
that can influence the adhesion of microbial cells to intestinal mucus (e.g., mucin glycan
residues and IgA proteins) [52].
Host gene composition and bacterial gene composition establish an obvious mutual
relationship in which metabolites and molecules interact, maintaining a balance between
the gut microbiota and the environment, as discussed in depth later. Bacteria can synthesize
metabolites on the basis of genetic composition (i.e., lipopolysaccharide (LPS), SCFAs
and amyloids) or regulate host gene expression by using miRNAs (which silence the
expression of target genes). Conversely, fecal miRNAs can regulate bacterial composition
by specifically targeting bacterial genes [53].
Sex hormones and gut microbiota influence each other and parallel metabolic and
immune changes through the lifespan [54]; interestingly, adoptive transferred male mi-
crobiota to recipient females resulted in elevated testosterone and metabolomic changes
and delayed the onset and severity of type 1 diabetes in a mouse model, suggesting that
the higher female risk for autoimmunity can be influenced by sex differences in the gut
microbiome [55].
Dietary habits and food types can influence microbial composition as well. The effect
of diet on gut microbiota has been investigated at several levels, from specific nutrients to
diet styles [56].
Antibiotics can strongly affect the components of gut microbiota: adult gut micro-
biomes seem not to be resilient to repeated antibiotic administration; furthermore, antibi-
otics taken early in life could deeply impact the gut microbiome composition, resulting in
predisposition to obesity, asthma, inflammatory bowel disease and other disorders such as
autoimmunity [57].
3.3. Gut Microbiota-Immune-Brain Interactions
An increasing number of studies have suggested that gut microbiota and CNS com-
municate constantly during life stages, connecting the emotional and cognitive centers of
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the brain with peripheral intestinal functions [46,58,59] via the microbiome–gut–brain axis
that consists of molecular pathways, belonging to the endocrine, immune, nervous, and
metabolic systems, interacting with each other [46,60–62]. The gut microbiota interacts with
the CNS by producing various metabolites ranging from sugars and SCFA to neurotransmit-
ters including serotonin, γ-aminobutyric acid (GABA), norepinephrine and dopamine [63].
Furthermore, it stimulates the peripheral immune system by inducing the release of cy-
tokines and chemokines which, in addition to locally regulating bacterial concentrations,
can infiltrate the blood and lymphatic system and therefore have effects on the CNS [63].
Moreover, it can interact with the CNS by stimulating the vagus nerve [63]. Conversely,
biochemical changes in the central nervous system can alter the microbial composition and
immune cell responses in the gut microbiome through the hypothalamic–pituitary–adrenal
(HPA) axis [63].
Interactions between the intestinal microbiota, the peripheral immune system and the
CNS are essential for the life of the host. Studies in germ-free (GF) rodents have shown the
crucial role of the microbiota in key aspects of neurodevelopment, neuroinflammation and
behavior, reviewed in detail in [46].
Gut associated lymphoid tissue (GALT) is composed of cells with innate and adaptive
immunity. The cells with innate immunity distinguish between potentially pathogenic
microbial components and harmless antigens by means of “pattern recognition receptors”
(PRRs), which allow mammalian cells to recognize characteristic conserved molecules
present on microorganisms and lead to activation of Th17, Treg and IgA-producing B cells
with adaptive immunity [64]. Mucous IgA secreted through the epithelium coats and
agglutinates their targets to prevent their direct interaction with the host. This avoids the
potentially harmful stimulation of the immune system in the mucous membranes by the
lumen contents and also preserves the regular composition of the microbiota [65].
In the lamina, 30/40% of the memory CD4+ T lymphocytes are Th17 cells. Under
physiological conditions, their typical cytokines, interleukin (IL)-17A, IL-17F and IL-22,
stimulate the production of antimicrobial proteins by intestinal epithelial cells and the
formation of tight junctions between these cells [66]; they also mediate IgA transport [67]
and neutrophil recruitment [68]. Consequently, Th17 cells play an indispensable role
in preventing infection by various species of pathogenic bacteria and fungi. Since Th17
cells can induce harmful inflammation, their response in the gut is strictly regulated by
induction of Treg cells. Intestinal Treg cells comprise both CD4(+) T cells that express Foxp3
and Tr1-like cells that produce IL-10 and can be generated in conditions that also promote
effector T cell responses; both play an important functional role in promoting tolerance to
food antigens and gut microbiota [69], as well as in suppressing tissue damage caused by
immune responses against pathogenic bacteria [70].
Specific bacteria preferentially induce specific CD4+ T subtypes. For example, seg-
mented filamentous bacteria (SFB) induce the differentiation of Th17 cells in the ileum,
while strains of Clostridia and Bacteroides fragile favor the differentiation of Tregs in the
colon. [71]. Gut-induced Th17 cells can became pathogenic under specific stimuli, such
as high IL-23 production, salt, or long chain fatty acids. They can migrate to the drain-
ing lymph nodes of target organs, such as the CNS, contributing to autoimmune disease
through cross-reactivity between microbial peptides and self-antigens (model of molec-
ular mimicry). Alternatively, microbiota-specific Th17 cells migrate towards the lymph
nodes and lower the activation threshold of self-reactive effector T cells (T cell threshold
model) [71], inducing a harmful immune response to self-antigens.
3.4. Evidences from Experimental Autoimmune Encephalomyelitis (EAE)
The first evidence of the involvement of gut microbiota in MS comes from experiments
on the EAE, the most commonly used model for MS, which resembles the inflammation and
demyelination processes of the human counterpart. Specific components of gut microbiota
have the capability to promote or prevent EAE. A first study by Berer et al. [72] showed
that a germ-free environment has been associated with a milder EAE disease course. This
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result was not surprising as germ-free mice show extreme defects in immune system
development, but clearly demonstrates the essential role of commensal-mediated immune
system development in this disease. GF EAE mice have lower levels of the proinflammatory
cytokines IFN-γ and IL-17A, both in the gut and the CNS, and display an increase in Treg
cells [73]. Of further note, gut microbiota influences blood-brain barrier (BBB) permeability
in mice. Germ-free mice have disrupted BBB tight junctions when compared to pathogen-
free adult mice. The permeability is overcome by colonization of the germ-free mice with
conventional gut flora. This observation suggests that early colonization by microflora may
be essential in the development of normal BBB function [74].
Intestinal colonization by segmented filamentous bacteria (SFB), a Clostridia-related
species that displays features between an obligate and facultative symbiont, promoted the
production of IL-17 in the intestine and induced the expansion of Th17 in the CNS [73].
The abundance of SFB, together with gut barrier function, is regulated by the IL-23R/IL-22
pathway. When the intestinal barrier is disrupted, systemic dissemination of microbial
products occurs, which invokes the IL-23 pathway and initiates barrier repair, as well
as Th17 responses aimed at neutralizing invading commensal microbes. Moreover, SFB-
induced-IL-23 results in production of IL-22 that triggers a complex circuit that promotes
IL-17 expression in T cells, especially in the terminal ileum, which is the site of SFB
attachment to the epithelium. SFB-induced activation may also result in the generation
of autoreactive Th17 cells in response to presentation of autoantigens in the setting of a
breached intestinal barrier [75].
Conversely, the Gram-negative bacteria Bacteroides fragilis, which also reside in the
human gut microbiome, promote immune homeostasis. Polysaccharide A (PSA), the
most abundant capsular polysaccharide expressed by B. fragilis, protected mice from EAE
by inducing conversion of CD4+ T-cells into IL-10-producing Foxp3+Tregs via Toll like
receptor (TLR)2 and suppressed Th17 responses [76,77]. Further oral administration of
PSA was associated with a lower “clinical” score and was able to stimulate the adaptive
immune system towards an anti-inflammatory status [76].
Moreover, dietary metabolites may influence systemic autoimmune response. SCFA
improved the course of EAE by long-lasting imprinting of gut-derived Treg cells, while
long-chain fatty acids (LCFA) exacerbated EAE disease and induced expansion of Th17
cells in the gut [78].
3.5. Evidences from Clinical Studies in MS Patients
Studies in MS are still at the early stage of development and limited to case-control
examinations of the gut microflora in MS patients versus healthy controls (Table 1). Al-
though changes in some commensal bacteria have been consistently detected in different
microbiota studies in MS, the results vary between different studies. These discrepancies
may reflect differences in the ethnic, genetic, lifestyle, and dietary backgrounds of the pa-
tient cohorts analyzed. However, some peculiarities have been highlighted in the intestinal
microbiota of subjects with MS compared to controls.
Decreased abundance of Clostridia [79], Bacteroides and Parabacteroides [79–81], Bu-
tyricimonas [82], Faecalibacterium [83], Prevotella [79–81], Lactobacillus [81], Adlercreutzia
and Collinsella [81] has been observed in MS subjects with respect to controls. Con-
versely, MS subjects showed increased abundance of Metanobrevibacter [82], Acinetobacter
calcoaceticus [80,84], Akkermansia muciniphila [78,80,82], Pseudomonas, Mycoplana, Blautia
and Dorea [81] with respect to controls. According to these observations, some relation-
ships involving the pathogenetic mechanism of MS can be conjectured. Firmicutes and
Bacteroitedes are SCFA producers, and SCFA metabolism has been related to MS patho-
genesis [24,25] and progression [85]. In particular, Faecalibacterium and Bacteroitedes are
butyrate and propionate producers. A reduced abundance of these bacteria in MS patients
can be associated with a decreased inhibition of the immune system inflammatory response
through the NF-Kb pathway by SCFAs [24] or with other mechanisms of immunetolerance,
including those related to Treg cells [24]. Notably, the polysaccharide A (PSA) of Bacteroides
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fragilis can induce IL-10 dependent enhanced conversion of Treg cells and protect against
autoimmunity [24]. An imbalance in Clostridia can exert diverse effects. Some clostridial
species found in reduced numbers in the gut microbiota of MS patients can induce colon
regulatory T cells (Tregs), which prevent autoimmunity and allergies [79].
Table 1. Gut microbiome studies in MS.
Observation/Microorganism Host Organisms Possible MS-Related Immunopathogenetic Mechanism Reference
Germ-free gut EAE mice
Milder disease course;
lower levels of IFN-γ and IL-17A in the gut and CNS;
Treg expanded in the CNS;




Segmented Filamentous bacteria (SFB) EAE mice Higher levels of IL-17 in the gut;Th17 expanded in the CNS [73]
Bacteroides fragilis EAE mice Polysaccharide A-mediated Tregs induction via TLR2 andsuppression of the Th17 response [76,77]
Decreased abundance of Clostridia [79],
Bacteroides and Parabacteroides [79–81],
Butyricimonas [82], Faecalibacterium [83],
Prevotella [79–81], Lactobacillus [81],
Adlercreutzia and Collinsella [81] with
respect to controls
MS patients
SCFA-producer bacteria induce IL-10 dependent enhanced
conversion of Treg cells and may be related to MS pathogenesis
and progression;
Clostridia can induce colon regulatory T cells (Tregs) and prevent
autoimmunity;
Epsilon toxin (ETX) produced by Clostridium perfringens has






Increased abundance of Metanobrevibacter
[82], Acinetobacter calcoaceticus [80,84],
Akkermansia muciniphila [80,82,84],
Pseudomonas, Mycoplana, Blautia and Dorea
[81] with respect to controls
MS patients
Methanogenic archaea can induce DCs activation;
Akkermansia and Acinetobacter have been associated with lower
Treg induction and increased Th1 polarization. MS fecal transplant
induced higher incidence of spontaneous EAE.
[24]
[80,82,84]
Conversely, MS subjects showed increased immunoreactivity to the Epsilon toxin
(ETX) produced by Clostridium perfringens [86], indicating prior exposure to ETX. ETX’s
tropism for the BBB and binding to oligodendrocytes/myelin makes it a stimulating
candidate for nascent lesion formation in MS [86]. Metanobrevibacters are methanogenic
archaea that can induce dendritic cell activation and pro-inflammatory effects on cells
with adaptive immunity [24]. Changes in the abundance of Akkermansia, Acinetobacter and
Bifidobacterium have been associated with impaired ability to promote the differentiation
of Tregs, or with the ability to promote Th1 cell differentiation in PBMC cultures [80,84].
Higher incidence of EAE after MS fecal transfer in GF mice has been observed [80] but
the roles of single taxa remain debated. For example, the effect of Akkermansia on MS is
controversial: studies from multiple cohorts found an increase of Akkermansia muciniphila in
MS gut microbiotas [80,84]; by contrast, Akkermansia showed anti-inflammatory properties
in EAE after fecal transplant from EAE-peak to EAE-susceptible mice, expanding Treg cells
by a mi-RNA dependent mechanism [87]. According to these observations it is evident that
the number of hypotheses that link specific microorganisms to MS pathogenetic mechanism
is constantly growing.
4. Interactions between Gut Microbiota and Host Genes
4.1. Heritability of Gut Microbiome
Associations between the human genome and microbiome composition have been
extensively studied in recent years. Microbiome and host genetics are strictly correlated [88]:
the first plays a role in human health and disease by influencing the host’s traits, disease
susceptibility, and treatment response; the second influences microbiome composition [89].
In particular, studies on twins demonstrated that the gut microbiomes of monozygotic
(MZ) twins are significantly more similar than those of dizygotic (DZ) twins, indicating
that host genetic factors are involved in modulating gut microbiome composition [88,90].
The first study by Goodrich et al. [91] was performed on a large cohort of MZ and DZ twin
pairs (977 individuals), which allowed them to assess the impact of genotype and early
shared environment on gut microbiota. This study was fundamental for the further and
larger study on the Twins UK cohort (416 twin pairs). This new study in 2016 demonstrated
significant heritability of overall microbiome composition [92]. Several heritable taxa
have been identified: the family Christensenellaceae has been demonstrated to have the
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highest heritability; however, the archaea family Methanobacteriacae, the phyla Firmicutes,
Actinobacteria, Tenericutes, and Euryarchaeota were shown to be more heritable, while the
highly abundant Bacteroidetes phylum shows very little heritability. In a Canadian cohort,
20 bacterial taxa were found to be heritable and included five taxa reported in the UK
cohort [93]. These results indicated that some bacteria are affected by host genetics in
the overall human population, whereas variation of the overall composition of the gut
microbiome is determined by environmental factors.
4.2. MGWAS Studies
In the last decade many microbiome genome-wide association studies (mGWAS)
have been conducted, performing both 16S RNA sequencing and whole-metagenome
sequencing to identify hosts’ genetic polymorphisms that interact with the microbiome
and influence its architecture and functional diversity [88–90,94]. Associations between
microbiome and variants located in genes involved in immunity and metabolism have
been found from these studies, despite the relatively small sample sizes of healthy subjects
(Table 2) [89].
The first study by Blekhman et al. [95] focused on 93 individuals and included host
information derived from Human Microbiome Project. Eighty-three associations were
identified between human loci and the microbiome using the shotgun metagenomic se-
quencing method, but only one association, between the lactase gene LCT, which encodes
lactase-phlorizin hydrolase (LPH) and the abundance of Bifidobacterium (from the phyla
Actinobacteria), has been validated in other cohorts. The LCT gene is an example of how
dietary changes affect the relationship between genetics and microbiome. SNPs at the
LCT locus that promote continued LPH production enable lactose metabolism in adults,
whereas LCT variants associated with reduced LPH activity are implied with lactose in-
tolerance and can promote the growth of lactose-fermenting bacteria in the colon, but
only if the individual consumes dairy products [90]. In the same year, a second mGWAS
was conducted by Davenport et al. using 16S rRNA sequencing on a larger cohort of
127 individuals living in North America. Results of the study demonstrated a correlation
between SNPs in regions of the phospholipase D1 PLD1 gene and abundance of the genus
Akkermansia [89,90,94–96]. In 2016 a major study was conducted by Wang et al. [97] using
16S rRNA to analyse microbiomes of more than 1800 healthy European subjects. By apply-
ing an analysis of variance (ANOVA) approach, the authors identified 42 host genetic loci
that affected β diversity, a measure of variability in gut microbiome composition between
different environments. Individually, each locus explained only a small proportion of the
total variability between different hosts, but together the loci explained almost 10% of the
inter-individual gut microbiome variability. In particular, it was shown that variants in one
of the identified loci, the Vitamin D Receptor (VDR) gene, were associated with microbiome
composition [97]. In the same study, by applying an alternative statistical method, 40 other
loci were found to be correlated with bacterial taxa and some genes were shown to affect
the composition of the gut microbiome, such as LCT, Fucosyltransferase 2 (FUT2) and
Nucleotide Binding Oligomerization Domain Containing 2 (NOD2), although these associ-
ations did not reach genome-wide significance [97]. Moreover, Turpin’s group performed a
family case study, applying 16S RNA sequencing to Canadian Caucasian asymptomatic
first-degree relatives of individuals with Crohn’s disease and to a replication cohort includ-
ing 270 individuals from 123 families [90,93]. They identified 20 taxa as being heritable:
seven new and 13 found in a previous twin study [97]. This information was confirmed
subsequently in a twin study using a different approach: whole-metagenome sequencing.
The same method was followed in 2016 by Bonder et al. [98], whose study included more
than 1500 healthy individuals in three different Dutch cohorts. The authors confirmed
the correlation between the LCT gene and Bifidobacterium abundance and identified nine
other human loci associated with bacterial taxa, as well as 33 loci associated with bacterial
functional pathways using a conventional P value threshold for GWAS (p < 5 × 10−8) [94].
One of the most recent studies [99] tried to replicate Blekhman’s results from the 2015 exper-
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iments: they considered the same cohort, but used more stringent thresholds. As a result,
their untargeted GWAS could not identify any significant associations, whereas the original
study identified 83 associations [89]. In another mGWAS performed in 2018 by Rothschild
et al. [100], 1046 healthy Israeli individuals who presented different ancestral origins and
who shared a relatively common environment were analysed. This study, which could not
be replicated, did not find any significant association between host genetic variations and
bacterial taxa, but in conclusion suggested that some bacterial taxa were heritable [89].
Table 2. Microbiome GWAS studies.
Study Year Sequencing Method Sample Size Notes Reference
Blekhman et al. 2015 Shotgun metagenomic n = 93 Variants in the LCT gene correlated withabundance of Bifidobacterium (p = 1.16 × 10−5). [95]
Davenport et al. 2015 16S n = 127 SNPs in regions of the PLD1 gene associatedwith abundance of genus Akkernabsia. [96]
Wang et al. 2016 16S n = 182
Forty-two loci included variants in VDR
gene-encoding
(vitamin D receptor) associated with beta
diversity (p < 5 × 10−8).
[97]





Identification of 20 possibly heritable taxa. [85,86,93]
Bonder et al. 2016 Shotgun Metagenomic n = 1514
Confirmation of variants in the LCT gene
correlated with abundance of Bifidobacterium.
Nine new human loci associated with bacterial
taxa and 33 loci associated with bacterial
pathways.
[98]
Rothschild et al. 2018 Shotgun Metagenomicand 16S n = 1046 No significant association detected. [100]
Kurilshikov et al. 2021 16S n = 18340
One SNP in the LCT locus correlated with
abundance of Bifidobacterium (p = 1.28 × 10−20).
FUT2 locus was suggestively associated with
the abundance of Ruminococcus torques.
[88]
Rühlemann et al. 2021 16S n = 8956
Thirty-eight genetic loci found to be associated
with single bacteria and overall microbiome
composition. ABO group was suggestively
associated with the abundance of
Faecalibacterium (P Meta = 6.16 × 10−9) and
Bacteroides (P Meta = 3.65 × 10−10).
[101]
In one of the most recent mGWAS published in Nature Genetics in 2021 [88],
18,340 healthy individuals from 24 cohorts were analysed to explore the host genetics
and gut microbiome composition. Despite the large sample size, only one SNP rs4988235
in the LCT locus which was correlated with the abundance of Bifidobacterium showed an
association at the genome-wide significance threshold (p = 1.28 × 10−20); this effect was the
strongest in the Hispanic/Latin American cohort. Thirty-one taxon-specific microbiome
trait loci (mbTLs), both for relative abundance or presence of microbial taxa, were identi-
fied as suggestive effects at a p < 5 × 10−8. Among them are the FUT2 locus, which was
associated with the abundance of Ruminococcus torques genus group, and three SNPs in the
9q21 locus which includes the gene GCNT1, encoding glycosyltransferase involved in the
biosynthesis of mucin, and the RFK gene, which encodes the enzyme that catalyses the
phosphorylation of riboflavin (vitamin B2). Even with the large sample size, the number
of mbTLs identified was rather modest and the authors suggested that a larger sample
size would have been necessary to increase the discovery rate. In this work [88], they also
confirmed the likely influence of microbiome on the gut–brain axis and on gastrointestinal,
brain and mood disorders.
In the same year, a GWAS studying 8956 German individuals [101] identified
44 genome-wide significant associations with microbial composition in 38 genomic loci.
Apart from the association of the LCT locus with Bifidobacterium, two independent univari-
ate associations with a locus surrounding the histo-blood group ABO system transferase
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(ABO) gene were identified as associated with the differential abundance of Faecalibacterium
(rs3758348, P Meta = 6.16 × 10−9) and Bacteroides (rs8176632, P Meta = 6.87 × 10−10). Bac-
teroides were also found to be significantly or suggestively associated with other variants in
BACH2 (P Meta = 4.58 × 10−10) and FUT2 (P Meta = 4.46 × 10−7) genes. The authors then
tried to infer the potential causal effect of microbiome on complex host traits by applying
Mendelian Randomization (MR) analysis. MR analysis was performed for all univariate
microbial features and 41 selected binary traits derived from the MR-Base database. None
of the microbial traits with causal effects reached the genome-wide significance threshold
at any locus, but some of them reached the suggestive threshold. It has been demonstrated
that among the 19 suggestive (P < 1.22 × 10−3) microbial effects on host traits, nine of
them were linked to IBD and Crohn’s disease. In particular, the presence of Bacteroides
associated with ABO histo-blood group status appeared to significantly protect against
Crohn’s disease development. Other MR results confirmed host–microbiome interactions
previously described in observational studies. For example, from both in vivo studies and
MR analysis, Parabacteroides were shown to have a protective effect on the “obesity class 2”
trait [101].
To conclude, SNPs identified as having significant associations with microbial taxa
did not overlap between the studies and replication of mGWAS results has been poor, apart
from the association with LCT locus and the abundance of Bifidobacterium. This can possibly
be explained by different statistical and technical methods, multiple-testing corrections
and intrinsic sample features (lifestyle, diet, demographic and environmental conditions
of subjects). However, the enrichment of microbiome-associated variants with immunity
and metabolism related genes remains consistent among the studies. In addition, previous
mGWAS have been conducted on a reduced number of individuals, mostly in Europe and
North America. Future studies should consider larger cohorts in order to increase the
power of these association studies, and including not only Western populations. In fact,
the association of host genetic variants with microbiomes may be dependent on ethnicities,
environment or intra-individual features, so studying diverse populations will help to
identify these interactions.
4.3. Evidence from Autoimmune Diseases and MS
As illustrated above, gut microbiome deeply influences the induction of immune
responses. This influence and its interaction with host genetics could play a fundamental
role in the development of autoimmunity, especially in those diseases in which genetic
factors interact with environmental ones (smoking, diet, air pollution, hormone fluctuation,
etc.) as risk factors, such as Inflammatory Bowel Disease (IBD), Rheumatoid Arthritis (RA),
Systemic Lupus Erythematosus (SLE) and MS. These diseases share a common genetic ar-
chitecture [30,102,103], increased pathogenic Th17 cells [104–106] and mechanisms related
to gut dysbiosis [107–109]. As currently there are no studies correlating host genetic factors
and microbiome in MS, in this review we describe this relationship in the abovementioned
diseases, concluding with a brief report of a first study in EAE.
IBD is a chronic immune-mediated disease of the gastrointestinal tract which has two
primary clinical manifestations: Crohn’s disease (CD) and ulcerative colitis (UC) [90,94].
IBD patients showed a decrease in the amount of Firmicutes and Bacteroidetes bacteria and
an increase in Proteobacteria and Actinobacteria compared with healthy controls [94]. IBD
susceptibility has a strong genetic component, with first-degree relatives (FDRs) of IBD
patients having a higher risk of developing IBD [94]. Since the contribution of genetics
and microbiome are clear, GWAS have been conducted to investigate the effect of host
genetics on the gut microbiome in individuals diagnosed with IBD. These studies have
led to the identification of more than 230 SNPs associated with IBD, even if they account
for only a portion of heritability [94]. The majority of the IBD risk variants are located
within immunity genes involved in interaction with the microbiome, confirming a role for
host–gut microbes interplay in disease pathogenesis [110]. The first risk variant for IBD
was mapped in the NOD2 gene, which has the highest OR of 3.1 in Crohn’s disease. NOD2
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is expressed in gut epithelial cells, lymphocytes, monocytes and macrophages, acting as
a defensive factor against intracellular bacteria and commensal microbes. It encodes an
intracellular pattern recognition receptor that interacts with muramyl dipeptide (MDP),
a peptidoglycan found in both Gram-positive and Gram-negative bacteria: the binding
of MDP to NOD2 induces activation of NK-B and MAPK and increases transcription of
pro-inflammatory cytokines. NOD2 deficiency results in a hyperinflammatory response
to commensal microorganisms, while mutations in NOD2 disrupt the delicate balance of
immune homeostasis, which can lead to IBD [94,110]. In a mGWAS of 474 individuals, an
enrichment of the family Enterobacteriaceae was found, especially Escherichia coli, in subjects
with NOD2 variants, supporting the idea that the proliferation of these bacteria is normally
controlled by the NOD2-initiated immune response [90,94]. This result was confirmed by a
second study conducted on 1514 healthy subjects in which NOD2 was highly correlated
with Escherichia coli abundance (4.6 × 10−6 < p < 1.3 × 10−4) [94]. Autophagy has also been
involved in IBD: ATG16L1, LRRK2 and IRGM, genes involved in the autophagic pathway,
have been identified as risk-associated loci for this disease, especially CD [94,111]. Fur-
thermore, two case-control studies confirmed the significant association between ATG16L1
risk allele T300A and changes in gut microbiome architecture [111–114]. It remains unclear
what direct role autophagy plays in IBD pathogenesis. Other GWAS studies identified
FUT2 as a risk locus for multiple diseases, including IBD and type 1 diabetes mellitus [90].
FUT2, which encodes a protein that transfers terminal fucose residues to mucin glycans,
is involved in barrier function and is responsible for secretion of the ABO histo-blood
group antigens in the mucosa [94,101]. Individuals carrying minor allele (A) lack ter-
minal fucose residues on mucin glycans and are called “non-secretors”; non-secretors,
who are homozygous for the loss of function nonsense mutation of the FUT2 gene, have
shown increased susceptibility to CD (OR 1.1, 95% CI, 1.071–1.143; p < 10−15). Moreover,
FUT2 non-secretors show a considerable decrease in the enrichment of Faecalibacterium, an
anti-inflammatory and butyrate-producing genus, and an increase in Proteobacteria, demon-
strating that FUT2 polymorphisms are associated with microbiome [90,94,111]. Recently,
in a cohort of 33 healthy individuals it was possible to replicate these results [94,115], even
if they did not find a confirmation in a larger study of 1503 healthy twins [94,116].
RA is a multisystemic chronic autoimmune disorder that can affect the joints [117]. So
far, studies at a genome-wide level have identified only 349 genetic variants associated
with RA, explaining a small portion of heritability and disease pathogenesis. In parallel,
it has been demonstrated that the composition of gut microbiome is different among
patients, is heritable in 30% of patients and may be implicated in the pathogenesis as well.
Therefore, genetic variants that cause a predisposition to RA may also be responsible for
the interactions between microbiome, which explains part of the missing heritability, and
RA pathogenesis. These risk loci are associated with immune function, as they mediate the
transition to a pro-inflammatory phenotype, and they may involve the gut microbiome in
this switch [117]. Dysbiosis has already been observed between RA patients and matching
healthy controls, with Prevotella copri (P. copri) being the most variable bacterium in the two
conditions (results confirmed in four of seven studies). Moreover, patients with an early
disease onset showed immune activation against a P. copri peptide, Pc-27: in these patients,
IgA and IgG responses were registered compared to controls. It is still to be clarified if the
Prevotella–RA association is due to the host inflammatory condition or if it is causal [117].
In addition, transfer of fecal microbiota from mice susceptible to arthritis to germ-free mice
led to an increase in susceptibility to the disease [118,119].
SLE is an autoimmune disease in which the immune system attacks its own tissues
(joints, skin, brain, lungs, kidneys, and blood vessels), causing widespread inflammation
and tissue damage in the affected organs. For what concerns the genetic component
of the disease, about 100 risk loci have been identified, mostly in European and Asian
populations [120]. Even if there are few studies on the association between microbiome
and SLE, dysbiosis in patients has been observed. In particular, four independent studies
(from Spain, China, and Netherlands) [109,121–123], with varying cultural, dietary, and
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geographic data, reported in patients a decrease in Firmicutes bacteria and an abundance
of Bacteroidetes compared to healthy controls [118]. Another recent study found seven in-
creased bacterial species and 19 decreased ones in SLE subjects, but none matched with the
taxa previously identified in the aforementioned Chinese study [122]. An important study
conducted on mice revealed Enterococcus gallinarum to promote a lupus-like disease [124].
E. gallinarum is a Gram-positive gut commensal bacterium of the Firmicutes which causes
production of autoantigens, type I IFN and pro-inflammatory cytokines. Obviously, other
studies are required to understand if the discrepancy between Firmicutes and Bacteroidetes
is causal of the disease or is a consequence of it, and if this can affect the pathogenicity of
other bacteria such as E. gallinarum [118].
The role of host genetics has been investigated in several animal models due to better
control of genetics and environmental factors. Mouse models are considered a powerful
model for evaluating host–microbiota interactions applicable to humans for two main
reasons: high genetic similarity and similarity to humans at the microbial taxonomic
level. For example, genetic background (i.e., BALB/c or C57BL/6J) has shown to be
a stronger determinant than gender on the mouse microbiome [125], and the relative
abundance of several heritable microbial taxa such as Lactobacillus johnsonii was identified
as being affected predominantly by host genetics [126]. In the context of MS, a first study
assessing the role of gut microbiome and host genetic interaction was recently performed
on EAE [127]. Montgomery et al. demonstrated potent effects of host genetics on both
EAE susceptibility and gut microbial composition predating disease onset. By using a
genetically diverse mouse model representing 29 unique host genotypes, they studied
EAE by microbiome sequencing and targeted microbiome manipulation. They identified
specific gut bacteria and their metabolic functions associated with lower or higher EAE
susceptibility across multiple host genotypes, implicating short-chain fatty acid metabolism
as a key element conserved across multiple host genotypes: Lactobacillus reuteri was found
as a commensal species capable of exacerbating EAE [127]. These results demonstrate the
existence of complex interactions between host genetics and gut microbiota that modulate
susceptibility to CNS autoimmune disease, providing insights into microbiome-directed
strategies aimed at lowering the risk for autoimmune disease.
5. Conclusions
Research in the past decade has illustrated a close relationship between a host’s
microbiome and health, which leads to questions about how these microbiotas form and
whether host genes play a role. To date, the impact of host genetics on the composition
of the gut microbiome remains unclear. Several studies in mouse models and humans
support the idea that host genetic components can regulate gut microbiome composition:
twin studies have shown that overall microbiome composition and many individual taxa
are heritable. However, other studies in humans provide evidence for the dominant role
of the environment in shaping the gut microbiome, while host genetics plays a negligible
role. Although much effort has been invested, a clear trend indicating a role of the host
genetics in the gut microbiome has not been identified, probably due to inconsistencies and
unevenness between the studies’ results, low sample sizes and environmental factors [128].
Despite relatively strong epidemiological associations, the role of the microbiome in
MS remains complex and unclear. It is now widely accepted that the gut microbiota plays a
crucial role in the gut–brain axis, thus controlling CNS diseases, and dysbiosis is present in
MS patients; however, we are very far from the identification of a particular gut microbiome
signature in MS. This is mainly due to differences in geographical cohorts, sequencing
techniques, stage of disease and treatment across the studies. However, the gut microbiome
has emerged as a new environmental factor that could contribute to disease risk. At the
same time, genetic architecture is also known to be involved in disease susceptibility;
therefore, there is a strong need to understand how and if host genetics influence gut
microbiome composition. The elucidation of this interaction could help in explaining the
missing heritability determined by the interactions between environmental factors and
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genes. Studies in this direction are in their infancy, but a collective effort in this direction
would be desired, addressing critical challenges such as increased sample size, independent
replication, meta-analysis in multiple populations, and environmental factors. Overall,
the comprehension of host genetics and gut microbiome composition at the onset of the
disease could be a challenge for the design of personalized therapeutic strategies.
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